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c Institute of Personalized Cancer Therapy, The University of Texas MD Anderson cancer center, United StatesPatients with a family history of cancer are being evaluated with consistentwith a RTS diagnosis. Themissense variant PRSS1 p.N29I is pre-
single-gene or gene panel tests (LaDuca et al., 2014). The decreasing
cost and potential to provide comprehensive genetic risk assessment
makes whole genome sequencing (WGS) an attractive tool for under-
standing the genetic risk for cancer (Collins and Hamburg, 2013). De-
spite such potential, the empirical value of WGS in cancer genetics
clinics is unknown: whether WGS can replicate previous ﬁndings in
single/multi-gene testing, and whether it will increase the rate of
identiﬁcation.
In this issue of EBioMedicine, Foley et al. describes their results
obtained from analyzing the WGS data from the blood samples of two
cohorts of cancer genetics patients: those with BRCA1/2 mutations
(n = 176) and those without (n = 82) (Foley et al., 2015-in this
issue). In their analysis, they focus on a set of 163 clinically relevant
genes, including those on commercial cancer-susceptibility gene panels,
recommended by American College of Medical Genetics (Green et al.,
2013), and those that might impact reproductive decision-making
(Dorschner et al., 2013). They ﬁnd that in each BRCA1/2 patient there is
an average of 6.8–6.9 potentially pathogenic variants (PPVs), deﬁned as
nonsynonymous variants with allele frequency b1% in a normal human
population (ESP6500). All the previously known BRCA1/2 mutations
are detected, proving the sensitivity of WGS.
As anticipated, most of these PPVs aremissense variants, themajority
of which will be classiﬁed as variants of unknown signiﬁcance (VUS)
based on existing knowledge (Biesecker, 2012). To facilitate diagnoses,
Foley et al. further restrict analyses to only loss-of-function (LoF) PPVs, in-
cluding nonsense, nonstop single nucleotide variants (SNVs) and frame-
shift indels (Foley et al., 2015-in this issue). In six patients, they identify
LoF PPVs in four dominant cancer-associated genes (CHEK2, ATM,
RAD50, and CDKN2B), in addition to original clinically diagnosed BRCA1/
2 mutations. These variants that carry additional cancer risk may be of
use for counseling and then screening of the patient's family members.
Interestingly, they ﬁnd that previously reported pathogenic missense
variants in several genes do not associate with their predicted diseases.
For example, the missense variant CREBBP p.N1978S is previously report-
ed as pathogenic and diagnostic for Rubenstein Taybi syndrome (RTS)
(Roelfsema and Peters, 2007). However, a patient carrying this variant
and her family members that carried the variant have no symptomsDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.12.003.
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,viously associatedwithhereditary pancreatitis and subsequent pancreatic
cancer. None of nine patients that carried the PRSS1-variant report any
pancreatic problems. These results indicate that while WGS can expand
the breadth of disease risk analysis, clinical interpretation ofWGS results
particularly for missense variants, requires detailed medical histories and
results from extended family members to derive conﬁdent diagnoses for
appropriate genetic counseling.Moreover, previously reporteddisease as-
sociations should be understood with caution and be interpreted in light
of available family medical history.
Among the 82 unrelated non-BRCA patients,WGS identiﬁes 6.4 PPVs
per non-patient in the 163 genes, including LoF PPVs in 14 genes in 18
(22%) patients. Notably, of the 13 individuals with LoF PPVs in cancer-
associated genes, 11 are in genes implicated in the individual's primary
cancer diagnosis and two provided a likely genetic diagnosis based on
family history. WGS also detects LoF PPVs in cancer genes such as
PALB2 and RAD51C, which are beyond tests performed as standard of
care for this population. This again illustrates the potential of WGS to
identify co-occurring mutations that pose genetic risks beyond the
patient's primary diagnosis or that may be modiﬁers of cancer risk.
To increase the diagnosis rate to the non-BRCA patients, the authors
expand analysis to include genes annotated in the ClinVar database
(Landrum et al., 2014). They identify LoF SNV PPVs in previously unsus-
pected cancer genes that are not considered as part of standard clinica
care, including ERCC3, FANCA and FANCM, which are good candidates for
further research.
In total, WGS provides possible genetic cancer risk PPVs in 20.7% of
non-BRCA1/2 clinic patients, doubling the rate (10.6%) of a recent report
using a targeted 42 gene panel of non-BRCA1/2 patients (Kurian et al.
2014). It is clear that WGS can enhance discovery of additional PPVs
However, it should be emphasized that at this time for many of these
additional genes, adequate natural history data is lacking, making ap-
propriate genetic counseling, risk assessment, and recommendations
for future screening and preventive strategies very challenging. Thus
signiﬁcant research efforts in larger patient cohorts will be needed be-
fore clinical WGS is widely adopted. The value of WGS will further in-
crease as clinical evidence becomes available for additional variants
particularly copy number variants and variants in non-coding regions.
Overall, this study highlights the ongoing discussion as to the appro-
priateness and use of WGS to balance the research goals to improve fu-
ture health carewith the goals of improving current patients' health and
16 K. Chen, F. Meric-Bernstam / EBioMedicine 2 (2015) 15–16well-being. It also indicates that increasing the clinical use of WGS will
require large-scale efforts to consolidate WGS results with clinical data
to improve accuracy of interpretation of rare variants, and to determine
optimum management strategies.
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